ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head
90% Of Participants Happy With Switch
Executive Summary
A new head-to-head proves Cabenuva is a match for Gilead’s Biktarvy, which should boost uptake of the long-acting HIV treatment.